Summit Therapeutics Inc (SMMT) said Monday it will collaborate with Pfizer (PFE) on a set of clinical trials to evaluate ivonescimab, its investigational drug, in combination with several Pfizer antibody drug conjugates to treat multiple solid tumors.
Financial terms were not disclosed.
Under the agreement, Summit will provide ivonescimab, while Pfizer will conduct the studies, which are planned to begin mid-2025 and will be overseen by both companies.
Each study will evaluate ivonescimab in combination with one of Pfizer's vedotin ADCs in distinct solid tumor settings to determine the safety profile and potential tumor-fighting ability of the combinations.
Summit shares were up 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.